the process for expediting certain drugs has improved dramatically over the last decade yet , we need to keep the pressure on our representatives lest they forget there is still a lot of work to be done in finding a treatment for kennedy 's disease nord issues statement on president trump s address to congress posted by jennifer huron nord issues statement on president trump s address to congress washington , d c , march , the national organization for rare disorders nord , the leading independent nonprofit organization representing the million americans with rare diseases , issued the following statement in response to president trump s first speech to congress yesterday evening , president trump recognized rare disease day and the million americans living with a rare disease in his first address to congress we are grateful for his recognition of the day that raises awareness for all individuals with rare diseases and their families we are elated that he is joining us in our efforts president trump also recognized megan crowley , and her father john , as shining examples of the untiring , steadfast commitment individuals with rare diseases and their families bring to finding treatments and cures for their disease the crowleys are one of many superstar families that deserve recognition , and we are thrilled that their tireless work was recognized on such a large stage the president continued , stating , our slow and burdensome approval process at the food and drug administration keeps too many advances , like the one that saved megan s life , from reaching those in need if we slash the restraints , not just at the fda but across our government , then we will be blessed with far more miracles like megan we agree that fda review processes can be improved upon to expedite the development and review of orphan drugs yet we disagree with the president that restraints must be slashed , or that the approval process at the fda is preventing advances from reaching those in need between and , percent of the rare disease treatments reviewed by the fda received an expedited review , compared to percent of treatments for common diseases i seventy eight percent of rare disease treatments were approved using one or more flexible development approaches generally defined as an approach that does not include two adequate and well controlled trials or uses novel endpoints ii for patients with immediately life threatening illnesses who cannot participate in clinical trials , the fda approves percent of all expanded access requests submitted by physicians and companies to read the rest of the statement follow this link nord statement